SLS Stock Rises 2% Overnight as Healthcare Execs Tout AML Drug GPS 'Game Changer', Regal Trial Hits 78 of 80 Trigger Events
According to LinkedIn discussions highlighted on Stocktwits, Sellas Life Sciences (SLS) stock rose 2% overnight Sunday after healthcare executives, including employees from AstraZeneca and Johnson & Johnson, publicly called the company's acute myeloid leukemia drug galinpepimut-S (GPS) a "game
GateNews·08-31 02:31


